Sign in
Taking people in United StatesPhase 3

Compares opevesostat with abiraterone or enzalutamide in advanced prostate cancer

Tests opevesostat against standard hormone drugs in men with spreading prostate cancer.

Key facts

Who runs it
Merck Sharp & Dohme LLC
Where
Aberdeen, Atlanta, Aurora, Austin, Bala-Cynwyd, Baltimore, Billings, Carmel, Charleston, Charlottesville, Cleveland, Dallas, Detroit, Elmhurst, Fairfax, Fort Myers, Gahanna, Germantown, Grand Rapids, Highlands Ranch, Houston, Irvine, Lakewood, Las Vegas, Lexington, Lone Tree, Los Angeles, Marshall, Miami Beach, Milwaukee, Mitchell, Naperville, New Brunswick, New Haven, Omaha, Orange, Palo Alto, Pembroke Pines, Peoria, Philadelphia, Pierre, Redlands, Richmond, Riverside, Roanoke, Sacramento, Saint Louis Park, Saint Paul, San Francisco, Sioux Falls, Spokane, Syracuse, Towson, Tucson, Vallejo, Vancouver, Washington D.C., Yankton, and Zanesville, United StatesSee the 63 sitesAlso in 38 other countries, 260 sites
Trial code
Registry title
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Status
Recruiting
Phase
Phase 3
People taking part
1,314 people, planned
Started
18 Dec 2023
Expected to end
2 Dec 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Opevesostat
  • Dexamethasone
  • Fludrocortisone acetate
  • Hydrocortisone
  • Abiraterone acetate
  • Prednisone acetate
  • Enzalutamide
Record updated
20 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with prostate cancer that has spread and no longer responds to hormone-lowering treatment, and that grew after one next-generation hormonal agent.

Age
18 years or older
Sex
All sexes
Disease stage
Prostate cancer (adenocarcinoma, no small cell type) that has spread to other parts of the body and kept growing during hormone-lowering treatment (ADT)
Earlier treatment
Disease grew during or after one next-generation hormonal agent (NHA) given for at least 8 weeks (at least 14 weeks if the bone disease grew). Had a PARP inhibitor, or was judged unable to take it, or refused it. No more than 6 cycles of docetaxel. No taxane chemotherapy for castration-resistant disease.
Biomarker or test result
Testosterone below 50 ng/dL (below 1.7 nM) on ongoing ADT. Fresh tumor tissue from a biopsy must be provided.

Main reasons for not taking part

  • Active cancer in the brain or its lining that is not treated and stable
  • Heart or blood vessel disease, long QTc syndrome, serious heart rhythm problems, or blood pressure out of range
  • Seizure within 6 months or a condition that may cause seizures
  • Poorly controlled diabetes or pituitary problems
  • Active hepatitis B and hepatitis C infection at the same time

The registry criteria, word for word

Show all 43 criteriaShow less

Who can take part

  • The main inclusion criteria include but are not limited to the following:
  • Have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell histology
  • Has prostate cancer progression while receiving androgen deprivation therapy (ADT) (or post bilateral orchiectomy) within 6 months before screening
  • Has current evidence of distant metastatic disease (M1 disease) documented by either bone lesions on bone scan and/or soft tissue disease shown by computed tomography (CT)/magnetic resonance imaging (MRI)
  • Has disease that progressed during or after treatment with one next-generation hormonal agent (NHA) for hormone sensitive prostate cancer (HSPC) (metastatic hormone-sensitive prostate cancer [mHSPC] or non-metastatic hormone-sensitive prostate cancer [nmHSPC]), or castration-resistant prostate cancer (CRPC) (metastatic castration-resistant prostate cancer [mCRPC] or non-metastatic castration-resistant prostate cancer [nmCRPC]), for at least 8 weeks of NHA treatment (at least 14 weeks of NHA treatment for participants with bone progression). Note: Participants may have received abiraterone acetate and docetaxel or darolutamide and docetaxel for HSPC. However, participants must have received no more than 6 cycles of docetaxel and had no radiographic disease progression while receiving docetaxel
  • Has had prior treatment with poly (ADP-ribose) polymerase inhibitor (PARPi) or were deemed ineligible to receive treatment by the investigator or have refused PARPi treatment
  • Has ongoing androgen deprivation therapy (ADT) with serum testosterone <50 ng/dL (<1.7 nM)
  • Has an eastern clinical oncology group (ECOG) performance status of 0 or 1 assessed within 10 days before randomization
  • Has adequate organ function
  • Has provided tumor tissue from a fresh core or excisional biopsy from soft tissue not previously irradiated. Samples from tumors progressing at a prior site of radiation are allowed
  • Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load before randomization
  • Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening
  • Participants who have adverse event (AEs) due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement or participants who have ≤Grade 2 neuropathy or ≤Grade 2 osteopenia/osteoporosis are eligible
  • Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)

Who cannot take part

  • Has a history of seizure(s) within 6 months before providing documented informed consent (IC) or has any condition that may predispose to seizure within 12 months prior to the date of enrollment
  • Has received a taxane-based chemotherapy for metastatic castration-resistant prostate cancer (mCRPC)
  • Has not adequately recovered from major surgery or have ongoing surgical complications
  • Is currently being treated with Cytochrome P450 (CYP450)-inducing antiepileptic drugs for seizures
  • Participants on an unstable dose of thyroid hormone therapy, as judged by the investigator, within 6 months before the start of the study intervention
  • Receives prior radiotherapy within 2 weeks before the first dose of study intervention, or radiation-related toxicities, requiring corticosteroids
  • Receives prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study intervention
  • Has systemic use of strong Cytochrome P450 3A4 (CYP3A4) inducers and P-glycoprotein (P-gp) inhibitors within 2 weeks before the first dose of study intervention
  • Has received prior targeted small molecule therapy or NHA treatment within 4 weeks before the first dose of study intervention
  • Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention
  • Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration
  • Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, (ie, without evidence of progression) for at least 4 weeks as confirmed by repeat imaging performed during study screening, are clinically stable and have not required steroid treatment for at least 14 days prior to the first dose of study intervention
  • Has concurrent active Hepatitis B virus and Hepatitis C virus infection
  • Has presence of gastrointestinal condition
  • Has history of pituitary dysfunction
  • Has poorly controlled diabetes mellitus
  • Has any of the following at screening visit: Hypotension: systolic blood pressure (BP) <110 mmHg, or uncontrolled hypertension: systolic BP ≥160mmHg or diastolic blood BP ≥90 mmHg, in 2 out of the 3 recordings with optimized antihypertensive therapy
  • Has a history of active or unstable cardio/cerebrovascular disease, including thromboembolic events
  • Has a history of clinically significant ventricular arrhythmias or Mobitz II second degree or third-degree heart block without a permanent pacemaker in place
  • Has known hypersensitivity to the components or excipients in abiraterone acetate, prednisone or prednisolone, enzalutamide, fludrocortisone, dexamethasone, or opevesostat
  • Has known additional malignancy that is progressing or has required active treatment within the past 3 years
  • Has active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy is allowed
  • Active infection requiring systemic therapy
  • Has clinically significant abnormal serum potassium or sodium level
  • History or family history of long QTc syndrome
  • The main exclusion criteria include but are not limited to the following:
  • Is unable to swallow capsules/tablets
  • Has a "superscan" bone scan defined as an intense symmetric activity in the bones and diminished renal parenchymal activity on baseline bone scan such that the presence of additional metastases in the future could not be evaluated

Where in United States

Also in 38 other countries, 260 sites

  • Avera Cancer Institute - Aberdeen (Site 0123)Aberdeen, United StatesContact: Study CoordinatorTaking people
  • Northside Hospital-Northside Hospital Oncology Network (Site 0100)Atlanta, United StatesContact: Study CoordinatorTaking people
  • University of Colorado Anschutz Medical Campus (Site 0046)Aurora, United StatesContact: Study CoordinatorTaking people
  • Texas Oncology - Central/South Texas (Site 8003)Austin, United StatesContact: Study CoordinatorTaking people
  • MidLantic urology (Site 0022)Bala-Cynwyd, United StatesContact: Study CoordinatorTaking people
  • Baltimore Veterans Affairs Medical Center (Site 0069)Baltimore, United StatesContact: Study CoordinatorTaking people
  • Greenebaum Comprehensive Cancer Center (Site 0049)Baltimore, United StatesContact: Study CoordinatorTaking people
  • St. Vincent Frontier Cancer Center-Research (Site 0037)Billings, United StatesContact: Study CoordinatorTaking people
  • Urology of Indiana - Carmel (Site 0055)Carmel, United StatesContact: Study CoordinatorTaking people
  • Ralph H. Johnson VA Health Care System (RHJVAHCS)-Urology (Site 0083)Charleston, United StatesContact: Study CoordinatorTaking people
  • University of Virginia Health System (Site 0054)Charlottesville, United StatesContact: Study CoordinatorTaking people
  • University Hospitals Cleveland Medical Center (Site 0043)Cleveland, United StatesContact: Study CoordinatorTaking people
  • Texas Oncology - DFW (Site 8001)Dallas, United StatesContact: Study CoordinatorTaking people
  • Cancer Clinics of North Texas (Site 0077)Dallas, United StatesContact: Toll Free NumberNo longer taking part
  • Henry Ford Hospital (Site 0015)Detroit, United StatesContact: Study CoordinatorTaking people
  • Edward-Elmhurst Healthcare, Elmhurst Hospital-Nancy W. Knowles Cancer Center (Site 0074)Elmhurst, United StatesContact: Toll Free NumberNo longer taking part
  • Inova Schar Cancer Institute (Site 0017)Fairfax, United StatesContact: Study CoordinatorTaking people
  • Virginia Cancer Specialists (VCS) (Site 8004)Fairfax, United StatesContact: Study CoordinatorTaking people
  • Florida Cancer Specialists - South (Site 7003)Fort Myers, United StatesContact: Toll Free NumberNo longer taking part
  • Central Ohio Urology Group - Gahanna (Site 0098)Gahanna, United StatesContact: Toll Free NumberNo longer taking part
  • The West Clinic, PLLC dba West Cancer Center (Site 0063)Germantown, United StatesContact: Study CoordinatorTaking people
  • Cancer and Hematology Centers of Western Michigan (Site 0005)Grand Rapids, United StatesContact: Study CoordinatorTaking people
  • UCHealth Highlands Ranch Hospital (Site 0111)Highlands Ranch, United StatesContact: Study CoordinatorTaking people
  • Texas Oncology - Gulf Coast (Site 8002)Houston, United StatesContact: Study CoordinatorTaking people
  • CHAO Family Comprehensive Cancer Center and Ambulatory Care (Site 0120)Irvine, United StatesContact: Study CoordinatorTaking people
  • Colorado Clinical Research (Site 0067)Lakewood, United StatesContact: Study CoordinatorTaking people
  • Comprehensive Cancer Centers of Nevada (Site 0010)Las Vegas, United StatesContact: Study CoordinatorTaking people
  • OptumCare Cancer Care-Research Department (Site 0078)Las Vegas, United StatesContact: Study CoordinatorTaking people
  • University of Kentucky Chandler Medical Center (Site 0048)Lexington, United StatesContact: Toll Free NumberNo longer taking part
  • University of Colorado Health - Lone Tree Medical Center (Site 0112)Lone Tree, United StatesContact: Study CoordinatorTaking people
  • UCLA Hematology/Oncology - Santa Monica (Site 0044)Los Angeles, United StatesContact: Study CoordinatorTaking people
  • Avera Cancer Institute - Marshall (Site 0122)Marshall, United StatesContact: Study CoordinatorTaking people
  • Mount Sinai Braman Comprehensive Cancer Center (Site 0107)Miami Beach, United StatesContact: Study CoordinatorTaking people
  • Medical College of Wisconsin (Site 0020)Milwaukee, United StatesContact: Study CoordinatorTaking people
  • Avera Cancer Institute - Mitchell (Site 0121)Mitchell, United StatesContact: Study CoordinatorTaking people
  • Edward-Elmhurst Healthcare, Edward Hospital-Edward Cancer Center (Site 0075)Naperville, United StatesContact: Toll Free NumberNo longer taking part
  • Rutgers Cancer Institute of New Jersey (Site 0033)New Brunswick, United StatesContact: Study CoordinatorTaking people
  • Yale-New Haven Hospital-Yale Cancer Center (Site 0064)New Haven, United StatesContact: Study CoordinatorTaking people
  • Oncology Hematology West P.C. dba Nebraska Cancer Specialists (Site 0026)Omaha, United StatesContact: Study CoordinatorTaking people
  • University of California, Irvine (UCI) Health - UC Irvine Medical Center (Site 0040)Orange, United StatesContact: Study CoordinatorTaking people
  • Stanford Cancer Center (Site 0036)Palo Alto, United StatesContact: Study CoordinatorTaking people
  • Memorial Hospital West-Memorial Cancer Institute (Site 0109)Pembroke Pines, United StatesContact: Study CoordinatorTaking people
  • Illinois Cancer Care (Site 0104)Peoria, United StatesContact: Study CoordinatorTaking people
  • Fox Chase Cancer Center (Site 0076)Philadelphia, United StatesContact: Study CoordinatorTaking people
  • Avera Cancer Institute - Pierre (Site 0118)Pierre, United StatesContact: Study CoordinatorTaking people
  • Emad Ibrahim,MD,INC. (Site 0012)Redlands, United StatesContact: Toll Free NumberNo longer taking part
  • VCU Health Adult Outpatient Pavillion (Site 0061)Richmond, United StatesContact: Study CoordinatorTaking people
  • Kaiser Permanente Riverside Medical Center (Site 0099)Riverside, United StatesContact: Study CoordinatorTaking people
  • Blue Ridge Cancer Care (Site 0004)Roanoke, United StatesContact: Study CoordinatorTaking people
  • University of California Davis (UC Davis) Comprehensive Cancer Center (Site 0114)Sacramento, United StatesContact: Study CoordinatorTaking people
  • HealthPartners Cancer Research Center-HealthPartners Frauenshuh Cancer Center (Site 0072)Saint Louis Park, United StatesContact: Study CoordinatorTaking people
  • HealthPartners Cancer Research Center-HealthPartners Cancer Center at Regions Hospital (Site 0092)Saint Paul, United StatesContact: Study CoordinatorTaking people
  • San Francisco VA Health Care System (Site 0093)San Francisco, United StatesContact: Study CoordinatorTaking people
  • Avera Cancer Institute- Research (Site 0094)Sioux Falls, United StatesContact: Study CoordinatorTaking people
  • Spokane Urology (Site 0035)Spokane, United StatesContact: Study CoordinatorTaking people
  • Associated Medical Professionals - Urology (Site 0081)Syracuse, United StatesContact: Study CoordinatorTaking people
  • Chesapeake Urology (Site 0009)Towson, United StatesContact: Study CoordinatorTaking people
  • The University of Arizona Cancer Center - North Campus (Site 0073)Tucson, United StatesContact: Study CoordinatorTaking people
  • Kaiser Permanente-Kaiser Permanente, Vallejo Medical Center, Adult Oncology (Site 0101)Vallejo, United StatesContact: Toll Free NumberNo longer taking part
  • Northwest Cancer Specialists (Compass Oncology) (Site 8008)Vancouver, United StatesContact: Toll Free NumberNo longer taking part
  • MedStar Washington Hospital Center (Site 0103)Washington D.C., United StatesContact: Study CoordinatorTaking people
  • Avera Cancer Institute - Yankton (Site 0117)Yankton, United StatesContact: Study CoordinatorTaking people
  • Genesis Healthcare System (Site 0102)Zanesville, United StatesContact: Toll Free NumberNo longer taking part

About the trial

What the trial wants to find out

The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypothesis is that opevesostat is superior to alternative abiraterone acetate or enzalutamide with respect to overall survival (OS), in androgen receptor ligand binding domain (AR LBD) mutation positive and negative participants.

The 2 groups in the trial

  • Daily Corticosteroids + OpevesostatTreatment being tested

    Participants receive opevesostat 5 mg by oral tablets twice daily (BID) plus dexamethasone 1.5 mg by oral tablets and fludrocortisone acetate 0.1 mg oral tablet once daily (QD) continuously until disease progression. Hydrocortisone 100 mg (oral or intramuscular \[IM\]) will also be provided to participants for use as rescue medication.

    Treatment: Opevesostat, Dexamethasone, Fludrocortisone acetate, and Hydrocortisone

  • Alternative Next-Generation Hormonal Agent (NHA)Existing treatment, for comparison

    Participants receive abiraterone 1000mg QD by oral tablets plus prednisone 5 mg BID by oral tablets or enzalutamide 160 mg QD by oral tablets until disease progression.

    Treatment: Abiraterone acetate, Prednisone acetate, and Enzalutamide

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
MK-5684-004: A Phase 3, Randomized, Open-label Study of Opevesostat Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) (OMAHA-004)
Plain-language title
Compares opevesostat with abiraterone or enzalutamide in advanced prostate cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
20 October 2026